Here’s What Morgan Stanley Thinks About Danaher Corporation (DHR)

Danaher Corporation (NYSE:DHR) is one of the Best Stocks to Buy Before the Next Bull Run .

On April 22, Morgan Stanley lowered the price target on the stock from $270 to $255, while maintaining an Overweight rating on the shares. Earlier, on April 21, Jefferies analyst Tycho Peterson raised the price target on Danaher Corporation (NYSE:DHR) to $245 from $240 and maintained a Buy rating.

The ratings come after the company’s FQ1 2026 earnings were released on April 21. During the quarter, the company posted $5.95 billion in revenue, reflecting 3.66% year-over-year growth but falling short of the consensus by $41.51 million. On the bright side, the GAAP EPS came in at $1.45 and topped expectations by $0.03.

​Analysts at Morgan Stanley noted that they made changes to their valuation model following the Q1 results and the latest guidance from the company. Danaher expects second-quarter revenue to increase in the low single-digit percentage, while for the full year, revenue is expected to grow by 3% to 6%.

​On the other hand, Jefferies analyst Tycho Peterson noted Q1 results to be solid and mentioned that headwinds are abating for the company at a time when its valuation is not too demanding.

​Danaher Corporation (NYSE:DHR) is a global life sciences and diagnostics company operating through three segments: Biotechnology, Life Sciences, and Diagnostics.

While we acknowledge the risk and potential of DHR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than DHR and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Stocks to Buy While the Market Is Down and 14 Stocks That Will Double in the Next 5 Years. 

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.